Apteki Gemini (Gemini) has partnered with an affiliate of private equity firm Warburg Pincus to fund the firm’s growth plan.
Gemini is committed to providing low price drugs, high quality patient pharmaceutical care, and the widest product availability in the market.
Founded in 1990, Gemini operates pharmacies in Northern Poland, as well as a nationwide online business (www.aptekigemini.pl). The Company offers the lowest prices of drugs in the Polish market and this allows large groups of patient’s access to drugs, which they would otherwise not purchase. Gemini currently operates predominantly in Northern Poland but is planning to expand its operations across the country and therefore increase the access to low price drugs to the Polish market. The online business, Aptekagemini.pl, was established in 2012 and is the largest Polish e- pharmacy, selling a wide range of OTC and consumer products to patients and consumers nationwide. This business is well placed to see further growth and development.
Under the new partnership, Gemini will continue with its existing strategy managed by its current management team.
Aleksandra Kuźniak of Gemini, says:“I am excited by the opportunities to expand both the traditional business of Gemini as well as our ecommerce business. Our model of low prices, quality service and high drug availability is winning loyal customers, who often would not be able to purchase the medicines at all. We have recruited over 150 pharmacists in the last 12 months and also look forward to offering attractive career opportunities to ambitious pharmacists across Poland as we pursue our expansion plans beyond the Northern region. I look forward to partnering with Warburg Pincus as we enter a new stage in our development.”
Paul Best, Managing Director at Warburg Pincus, says: “As long term growth investors, actively committed to the Polish market, we are excited by the opportunity to partner with Gemini as they deliver high quality specialised pharmaceutical care to patients across Poland.”
The transaction is subject to customary closing conditions, including receipt of regulatory and third- party consents
